Senseonics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Commercial integration and DTC marketing have driven strong patient and prescriber growth, with Eversense 365 showing robust real-world performance and high retention. The pipeline includes Gemini and Freedom, aiming for fully implantable, invisible CGMs by 2028. Financials are strong, with >80% revenue growth and improved margins.
-
The meeting, held virtually, covered six proposals including director elections, executive compensation, auditor ratification, share authorization increase, and an equity plan. All proposals passed, with results to be reported on Form 8-K.
-
Q1 2026 revenue grew 85% year-over-year to $11.7M with gross margin at 58%, driven by strong Eversense 365 adoption and successful U.S. commercial integration. Full-year revenue guidance was raised, and over $100M in new capital was secured to support growth and product pipeline.
Fiscal Year 2025
-
Revenue grew 60% to $35.3M in 2025, with gross margin over 50% and patient base doubling in the U.S. The company expects 65–76% revenue growth in 2026, driven by European expansion, new product launches, and continued DTC investment.
-
A 365-day CGM sensor is driving a shift to a direct sales model in 2026, expected to boost revenue and margins. DTC campaigns and a growing nurse network are fueling rapid patient growth, while new products and pump integrations expand future opportunities.
-
Q3 2025 saw 90% revenue growth, record new patient starts, and margin expansion driven by Eversense 365 adoption and DTC marketing. Commercialization transition from Ascensia is on track, with 2025 revenue guidance at $35M and gross margins set to rise further.
-
Eversense 365 commercialization will transition in-house by 2026, ending the Ascensia partnership and enabling higher margins, direct investment, and unified control. Strong growth momentum continues, with record patient starts and expanded DTC efforts, while financial guidance and funding outlook remain robust.
-
Q2 revenue grew 37% year-over-year to $6.6M, driven by Eversense 365 adoption and expanded DTC marketing. Net loss narrowed to $14.5M, and full-year revenue is guided at $34–38M with gross margin of 32.5–37.5%. Cash position strengthened to $126.7M.
-
Eversense 365 CGM launch and integration with Sequel's Twist pump drove 24% revenue growth in Q1 2025, with strong U.S. adoption and rapid payer transitions. 2025 guidance is reiterated, targeting $34–38 million in revenue and a doubling of the global patient base.
-
A one-year implantable CGM is gaining traction in a $12B+ market, with strong payer coverage, a robust commercial partnership, and a pipeline of next-gen products. Patient base is expected to double, targeting profitability by 2027, with new launches and hospital integrations ahead.
Fiscal Year 2024
-
Eversense 365's U.S. launch drove strong patient and prescriber growth, with 2024 revenue steady at $22.5M and gross profit impacted by one-time transition costs. 2025 guidance targets $34–38M revenue, doubling the patient base, and improved margins, with a European launch planned for H2.
-
Q3 results met expectations, driven by the transition to a 365-day CGM, which has seen strong early adoption, especially among Type 2 diabetics. Strategic partnerships, expanded inserter networks, and a robust product pipeline—including the Gemini sensor—position the company for significant growth in 2025 and beyond.
-
FDA approval and U.S. launch of Eversense 365 drove record lead generation and strong early feedback. Q3 revenue declined due to inventory transition, but full-year sales are expected to accelerate as 365 adoption ramps and gross margins improve, with restructuring extending cash runway.
-
Q2 2024 saw 18% revenue growth year-over-year, driven by strong U.S. patient adoption and strategic initiatives, including the upcoming 365-day CGM launch and partnerships like Mercy Health. Full-year revenue is projected at $22–24 million, with Q4 acceleration expected.
-
CGM market growth is accelerating, driven by payer support and patient demand for longer-lasting, discreet sensors. The company is launching a 365-day sensor, advancing next-gen products, and expanding partnerships with major healthcare systems and distributors.